Exelixis, Inc. Reports Positive Phase 1 Data for XL281 at EORTC-NCI-AACR Symposium

GENEVA--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) today reported preliminary phase 1 data from a dose-escalation trial of XL281 in patients with advanced solid malignancies. XL281 is a novel, selective, and potent small molecule inhibitor of wild-type and mutant RAF kinases that have been implicated in human cancer. Gary K. Schwartz, MD, Chief, Melanoma and Sarcoma Service, Memorial Sloan-Kettering Cancer Center, and an investigator on the phase 1 trial, presented the data in a poster session (Abstract #383) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is being held October 21-24 in Geneva, Switzerland. The poster will be available today on the Exelixis web site.
MORE ON THIS TOPIC